Ayunan, Ansar B.
HRN: 24 30 78 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/03/2024
CLINDAMYCIN 300MG (CAP)
01/03/2024
01/09/2024
PO
300mg
Q8
Cellulitis Vs Abscess L Periorbital Area
Waiting Final Action
Indication: Empiric Type of Infection: BloodstreamSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes